Jiangsu Hengrui Medicine Co., Ltd. (600276.SS) Fundamentals
As of May 25, 2026
TL;DR — Jiangsu Hengrui Medicine Co., Ltd. (600276.SS) fundamentals as of May 25, 2026
Jiangsu Hengrui Medicine Co., Ltd. (600276.SS) trades at a trailing P/E of 48.2x and a P/B of 6.07x. Return on equity is 13.9%, return on invested capital is 11.8%, and the company carries a debt-to-equity ratio of 0.00. The current ratio sits at 8.08, free cash flow yield is 232.0%, and the dividend yield is 36.0%. PASS — clears all three quality screens.
For intrinsic value (DCF, owner earnings, Graham number) and the full 5-pillar score, see the 600276.SS overview page.
Full Fundamentals Table
Every key indicator we track for 600276.SS fundamentals, grouped by category. Industry median is shown where a sector classification is available.
| Metric | 600276.SS | Healthcare median | What it measures |
|---|---|---|---|
| Revenue (TTM) | View full statement | - | Trailing twelve-month total revenue |
| Net Income (TTM) | View full statement | - | Bottom-line profit after taxes and interest |
| Free Cash Flow (TTM) | View full statement | - | Cash from operations minus CapEx |
| EPS (TTM) | N/A | - | Earnings per diluted share |
| ROE | 13.9% | 14% | Return on Equity — net income / shareholder equity |
| ROA | 12.6% | - | Return on Assets — net income / total assets |
| ROIC | 11.8% | - | Return on Invested Capital — NOPAT / (debt + equity) |
| P/E (Trailing) | 48.2x | 22x | Price / earnings — how many years of profit to recoup price |
| P/B | 6.07x | 3.8x | Price / book value — premium over net assets |
| P/S | 11.33x | - | Price / sales — useful when earnings are noisy |
| EV/EBITDA | 35.7x | - | Enterprise value / EBITDA — capital-structure neutral |
| Debt / Equity | 0.00 | 0.55 | Leverage — lower = less reliance on debt |
| Current Ratio | 8.08 | - | Current assets / current liabilities — short-term liquidity |
| Dividend Yield | 36.0% | - | Annual dividend / current price |
5-Year Trend
Indexed revenue growth path for 600276.SS over the past five fiscal years (base = 100). Used as a quick sanity check on whether the top line is compounding or stalling.
Trend indexed from 1-year revenue growth rate. Full statement available in the analyst tier.
Industry Comparison
Across Healthcare, the median company prints P/E around 22x, P/B near 3.8x, ROE close to 14%, and a debt-to-equity ratio of 0.55. 600276.SS's reading on each metric is in the ratio table above — anything materially above the median valuation multiple deserves a thesis to justify the premium, anything materially below the median return-on-capital flags an operational gap.
Compare 600276.SS side-by-side with sector peers in the Healthcare stock list.
Quality Triple Check
Piotroski F-Score
Nine-point checklist for accounting quality and operational efficiency
7/9
PASS
Beneish M-Score
Earnings-manipulation detector — below -2.22 is healthy
-2.68
PASS
Altman Z-Score
Bankruptcy-risk model — above 2.99 is "safe zone"
383.63
PASS
Verdict: PASS — clears all three quality screens. Reasonable accounting hygiene, low manipulation risk, and bankruptcy-safe.
Next steps
- View the full 600276.SS overview for intrinsic value (DCF), margin of safety, and the 5-pillar VM Score.
- Check the 600276.SS beta page for volatility vs the S&P 500.
- Look at the 600276.SS P/E ratio page for the 10-year valuation context.
- Dig into the 600276.SS debt-to-equity page for leverage trends.
- Run your own model in the DCF calculator.
Frequently asked about 600276.SS fundamentals
What are the key fundamentals for Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)?↓
The core 600276.SS fundamentals are P/E 48.2, ROE 13.9%, ROIC 11.8%, debt/equity 0.00, and dividend yield 36.0%. The complete ratio table on this page covers revenue, net income, FCF, EPS, ROA, P/B, P/S, EV/EBITDA, and current ratio.
How does 600276.SS compare to its Healthcare peers?↓
The Healthcare sector median P/E is roughly 22x, ROE 14%, and D/E 0.55. 600276.SS prints P/E 48.2, ROE 13.9%, and D/E 0.00. Use the Industry Comparison row in the ratio table for the full diff.
Does 600276.SS pass the Quality Triple Check?↓
600276.SS passes 3 of 3 quality screens (Piotroski F-Score, Beneish M-Score, Altman Z-Score). Detailed verdict above.
How is "fundamentals" different from intrinsic value?↓
Fundamentals describe what the business looks like today: profit, cash flow, leverage, returns on capital. Intrinsic value uses those fundamentals as inputs to a DCF (or similar model) and discounts the future cash flows back to today. Use both — fundamentals tell you whether a business is healthy, intrinsic value tells you whether the price is fair.
How often does ValueMarkers update 600276.SS fundamentals?↓
Cached financial statements refresh every 12 hours. The ratio table on this page is rebuilt every 6 hours via Next.js ISR, and the underlying FMP data refreshes on each new earnings release.